Prognostic significance of autoimmunity during treatment of melanoma with interferon

New England Journal of Medicine

Volumn 354, Issue 7, 2006, Pages 709-718

  Gogas, Helen ^a   Ioannovich, John ^b   Dafni, Urania ^a   Stavropoulou Giokas, Catherine ^b   Frangia, Konstantina ^c   Tsoutsos, Dimosthenis ^b   Panagiotou, Petros ^b   Polyzos, Aristidis ^a   Papadopoulos, Othonas ^a   Stratigos, Alexandros ^a   Markopoulos, Christos ^a   Bafaloukos, Dimitrios ^a   Pectasides, Dimitrios ^a   Fountzilas, George ^a   Kirkwood, John M ^d  

^a UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINUCLEAR ANTIBODY; ANTITHYROID AGENT; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; DNA ANTIBODY; INTERFERON;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYALGIA; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; RETINOPATHY; RHEUMATOID ARTHRITIS; SKIN DEFECT; SKIN ULCER; THYROTOXICOSIS; TIME SERIES ANALYSIS; TUMOR RECURRENCE; VITILIGO;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANALYSIS OF VARIANCE; AUTOANTIBODIES; AUTOIMMUNITY; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 32644454916     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa053007     Document Type: Article

References (32)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
3. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
4. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
5. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-7.
6. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63.
7. Weijl NI, Van Der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993;11:1376-83.
8. Scalzo S, Gengaro A, Boccoli G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. Eur J Cancer 1990;26:1152-6.
9. Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995;18:272-8.
10. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82.
11. Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994;73:1621-4.
12. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996;19:81-4.
13. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983;9:689-96.
14. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987;123:1053-5.
15. Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma: a case study. Dermatologica 1991;183:239-45.
16. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
17. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10.
18. Vallisa D, Cavanna L, Berte R, Merli F, Ghisoni F, Buscarini L. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 1995;93:31-5.
19. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998;91:393-9.
20. Wesche B, Jaeckel E, Trantwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83.
21. Zuffa E, Vianelli N, Martinelli G, Tazzari P, Cavo M, Tura S. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukaemia. Haematologica 1996;81:533-5.
22. Gogas H, Pectasides D, Bafaloukos D, et al. Adjuvant biotherapy with high dose interferon in high-risk melanoma patients (preliminary results). Proc Am Soc Clin Oncol 2000;19:575a. abstract.
23. Cox DR. Regression models and lifetables. J R Stat Soc [B] 1972;34:187-220.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Franzke A, Peest D, Probst-Kepper M, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999;17:529-33.
26. [ Erratum, J Clin Oncol 1999;17:1330.]
27. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002;20:3703-18.
28. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997;7:891-6.
29. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
30. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50.
31. Dranoff G. CTLA-4 blockade: unveiling immune regulation. J Clin Oncol 2005;23:662-4.
32. Ribas A, Bozon VA, Lopez-Berestein G, et al. Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675, 206 in patients with advanced melanoma. Proc Am Soc Clin Oncol 2005;23:716s. abstract.